FI964537A0 - Förfaranden för användning av sönderdelningskatalysatorer för peroxinitrit, farmaceutiska kompositioner för peroxinitrit, farmaceutiska kompositioner för detsamma - Google Patents

Förfaranden för användning av sönderdelningskatalysatorer för peroxinitrit, farmaceutiska kompositioner för peroxinitrit, farmaceutiska kompositioner för detsamma

Info

Publication number
FI964537A0
FI964537A0 FI964537A FI964537A FI964537A0 FI 964537 A0 FI964537 A0 FI 964537A0 FI 964537 A FI964537 A FI 964537A FI 964537 A FI964537 A FI 964537A FI 964537 A0 FI964537 A0 FI 964537A0
Authority
FI
Finland
Prior art keywords
peroxynitrite
pharmaceutical compositions
methods
same
decomposition catalysts
Prior art date
Application number
FI964537A
Other languages
English (en)
Finnish (fi)
Other versions
FI964537A (sv
Inventor
Michael Keith Stern
Daniela Salvemini
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of FI964537A0 publication Critical patent/FI964537A0/sv
Publication of FI964537A publication Critical patent/FI964537A/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI964537A 1994-05-13 1996-11-12 Förfaranden för användning av sönderdelningskatalysatorer för peroxinitrit, farmaceutiska kompositioner för peroxinitrit, farmaceutiska kompositioner för detsamma FI964537A (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24249894A 1994-05-13 1994-05-13
PCT/US1995/005886 WO1995031197A1 (en) 1994-05-13 1995-05-09 Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor

Publications (2)

Publication Number Publication Date
FI964537A0 true FI964537A0 (sv) 1996-11-12
FI964537A FI964537A (sv) 1997-01-10

Family

ID=22915009

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964537A FI964537A (sv) 1994-05-13 1996-11-12 Förfaranden för användning av sönderdelningskatalysatorer för peroxinitrit, farmaceutiska kompositioner för peroxinitrit, farmaceutiska kompositioner för detsamma

Country Status (13)

Country Link
EP (1) EP0758892A1 (sv)
JP (1) JPH10500671A (sv)
CN (1) CN1222286C (sv)
AU (1) AU709553B2 (sv)
BR (1) BR9507643A (sv)
CA (1) CA2189528A1 (sv)
CZ (1) CZ323496A3 (sv)
FI (1) FI964537A (sv)
HU (1) HUT76327A (sv)
NO (1) NO964793L (sv)
NZ (1) NZ285648A (sv)
PL (1) PL317192A1 (sv)
WO (1) WO1995031197A1 (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
WO1996009053A1 (en) * 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
AU737650B2 (en) 1997-11-03 2001-08-23 Duke University Substituted porphyrins
DE69928655T2 (de) 1998-04-24 2006-08-24 Duke University Substituierte porphyrine
WO2000009111A2 (en) * 1998-08-11 2000-02-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibitors of amyloid formation
IL126953A0 (en) * 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
EP1013272A1 (en) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Manipulation of the activity of a nitric oxide radical production pathway for the treatment of diseases associated with the presence of oxygen free radicals
ATE552260T1 (de) 1999-01-25 2012-04-15 Nat Jewish Health Substituierte porphyrine und deren therapeutische verwendung
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
FR2806911B1 (fr) * 2000-03-28 2003-01-10 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
AU2002248366B2 (en) * 2001-01-19 2006-10-26 Aeolus Sciences, Inc. Cancer therapy
AU2002312194B8 (en) 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
CA2488500A1 (en) 2002-06-07 2003-12-18 Duke University Substituted porphyrins
DE10240343A1 (de) * 2002-08-27 2004-03-11 Schering Ag Peroxynitrit-Umlagerungskatalysatoren
US6946466B2 (en) 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US7705040B2 (en) * 2005-10-07 2010-04-27 The University Of Hong Kong Reagents for highly specific detection of peroxynitrite
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
WO2008094222A2 (en) 2006-10-06 2008-08-07 Trustees Of Princeton Porphyrin catalysts and methods of use thereof
WO2009027965A1 (en) * 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
RU2506083C2 (ru) 2008-05-23 2014-02-10 Нэшнл Джуиш Хелт Способ лечения поражений, ассоциированных с воздействием алкилирующих веществ
JP6571089B2 (ja) 2013-12-31 2019-09-04 アボット ダイアベティス ケア インコーポレイテッドＡｂｂｏｔｔ Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｉｎｃ． 電源内蔵式分析物センサ及びそれを使用するデバイス
RU2557655C1 (ru) * 2014-06-10 2015-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ФГБОУ ВПО "ИГХТУ") Никелевый комплекс 5,10,15,20-тетракис[3',5'-ди(2"-метилбутилокси)фенил]-порфина, проявляющий свойство стационарной фазы для газовой хроматографии
CN107573259A (zh) * 2017-09-25 2018-01-12 沅江华龙催化科技有限公司 一种金属卟啉催化芳香烯烃合成芳香腈的方法
EP4059496A1 (en) * 2021-03-18 2022-09-21 Institut Pasteur Mntbap and m(iii) n-substituted pyridylporphyrins (mnps) for use in reversing sepsis-induced microglial cells alteration(s), associated long-term cognitive impairment, and/or for treating sepsis or sepsis-associated encephalopathy (sae), and/or related short and/or long-term symptoms or complications thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764728B2 (ja) * 1985-04-30 1995-07-12 日本石油化学株式会社 新規なテトラピロ−ル医薬用組成物
EP0256036B1 (en) * 1986-01-02 1993-04-07 The University Of Toledo Production and use of purpurins, chlorins and purpurin- and chlorin-containing compositions
US4866054A (en) * 1986-05-13 1989-09-12 Chai-Tech Corporation Antioxidant metallo-organic treatment of inflammation
WO1989002269A1 (en) * 1987-09-08 1989-03-23 The Rockefeller University Use of metalloporphyrins to reverse the toxic effect of tumor therapy
EP0484027B1 (en) * 1990-11-02 1996-12-18 Zeneca Limited Polysubstituted phthalocyanines
WO1992008482A1 (en) * 1990-11-14 1992-05-29 Uab Research Foundation Compositions for reducing oxidative injury
FR2676738B1 (fr) * 1991-05-22 1995-05-05 Ir2M Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
GB9111689D0 (en) * 1991-05-31 1991-07-24 Johnson Matthey Plc Gallium compounds
ES2113952T3 (es) * 1991-07-19 1998-05-16 Monsanto Co Complejos de manganeso con ligandos macrociclicos nitrogenados eficaces como catalizadores para dismutar superoxidos.
WO1993010777A1 (en) * 1991-11-25 1993-06-10 Albion International, Inc. Composition and method for reducing free radical cellular oxidative stress in warm-blooded animals
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions

Also Published As

Publication number Publication date
NO964793L (no) 1997-01-06
FI964537A (sv) 1997-01-10
WO1995031197A1 (en) 1995-11-23
AU709553B2 (en) 1999-09-02
NZ285648A (en) 1999-08-30
CN1222286C (zh) 2005-10-12
PL317192A1 (en) 1997-03-17
CZ323496A3 (en) 1997-10-15
CN1152871A (zh) 1997-06-25
HU9603140D0 (en) 1997-01-28
BR9507643A (pt) 1997-09-23
HUT76327A (en) 1997-08-28
EP0758892A1 (en) 1997-02-26
JPH10500671A (ja) 1998-01-20
NO964793D0 (no) 1996-11-12
AU2512095A (en) 1995-12-05
CA2189528A1 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
FI964537A0 (sv) Förfaranden för användning av sönderdelningskatalysatorer för peroxinitrit, farmaceutiska kompositioner för peroxinitrit, farmaceutiska kompositioner för detsamma
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
NO965377D0 (no) Indolinonforbindelser samt farmasöytiske preparater inneholdende forbindelsene
HUP9900625A3 (en) Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds
HUP0003309A3 (en) Imidazolyl-cyclic acetals, process for producing them and pharmaceutical compositions containing the same
HUP9902455A3 (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
HK1028769A1 (en) 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof
DE59507593D1 (de) Gaserzeugendes, azidfreies Stoffgemisch
NO976121L (no) FremgangsmÕte for fremstilling av karbonylforbindelser
NO983068D0 (no) FremgangsmÕte for fremstilling av bis-syklopentadienyl-dien komplekser
NO904222L (no) Fremgangsmaate for fremstilling av benzodiazepiner.
NO941648L (no) Fremgangsmåte for fremstilling av katalysatorer
FI101472B1 (sv) Förfarande för framställning av monoestrar av 1,3-dioler
FI973644A (sv) Nytt förfarande för framställning av 2,3-dihydrobenzofuranolderivat
ZA97872B (en) Use of pyrolidine derivatives for the manufacture of medicaments.
FI956058A (sv) Förfarande för framställning av glutardialdehyd
NO985535D0 (no) FremgangsmÕte for fremstilling av 1,3-alkandioler
NO996432D0 (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
DZ2302A1 (fr) Produit pharmaceutique cristallin.
FI964829A (sv) Förfarande för framställning av 2,2,4-trimetyl-1,3-pentandiolisobutyrat
FI961178A (sv) Förfarande för framställning av cykliska cis-1-amino-2-alkanoler
TR199601018A1 (tr) Farmasötik bilesikler.
FI972694A0 (sv) Nytt förfarande för framställning av sameridin
FI971964A0 (sv) Förfarande för framställning av 1-halo-3-trialkylsilanylbensenderivat
FI934317A0 (fi) Farmaceutiska sammansaettningar, vilka innehaoller ej-joniska ytaktiva aemnen

Legal Events

Date Code Title Description
MA Patent expired